Details

Autor(en) / Beteiligte

• Tachibana, Takayoshi
• Kanda, Junya
• Ishizaki, Takuma
• Najima, Yuho
• Tanaka, Masatsugu
• Doki, Noriko
• Fujiwara, Shin-ichiro
• Kimura, Shun-ichi
• Onizuka, Makoto
• Takahashi, Satoshi
• Saito, Takeshi
• Mori, Takehiko
• Fujisawa, Shin
• Sakaida, Emiko
• Matsumoto, Kenji
• Aotsuka, Nobuyuki
• Goto, Moritaka
• Watanabe, Reiko
• Shono, Katsuhiro
• Usuki, Kensuke
• Tsukada, Nobuhiro
• Kanamori, Heiwa
• Kanda, Yoshinobu
• Okamoto, Shinichiro

Titel

Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis

Ist Teil von

• Leukemia, 2019-11, Vol.33 (11), p.2610-2618

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• A multicenter retrospective study was performed to explore a prognostic scoring index in order to identify a population who are least likely to benefit from allogeneic hematopoietic cell transplantation (HCT) in patients with relapsed or refractory acute myeloid leukemia (AML). The cohort included 519 patients with AML, who received HCT between 2005 and 2015 at a status of relapse or primary induction failure. Multivariate analysis demonstrated five independent predictors for OS, including C-reactive protein ≥ 1 mg/dL, peripheral blood blast fraction ≥ 20%, poor-risk karyotype, performance status ≥ 2, and bone marrow unrelated donor as a stem cell source. A prognostic scoring index was explored based on these predictors, and successfully separated the cohort into four groups. At 2 years, OS was 47%, 24%, 8%, and 0% for Good (Score 0, 1: n  = 118), Intermediate-1 (Score 2: n  = 75), Intermediate-2 (Score 3: n  = 39), and Poor (Score 4: n = 24), respectively ( P  < 0.001). The predicting value of the index was confirmed in a validation cohort. Although a further validation study is warranted, the scoring index may be useful to predict survival and to identify the population with the lowest survival prior to HCT in patients with relapsed or refractory AML.